Tofacitinib versus Etanercept como tratamiento de artritis reumatoide en adultos entre 45-55 años

Abstract

Title: Tofacitinib versus Etanercept as a Treatment for Rheumatoid Arthritis in 44-45 Year-Old Adults Objective: This research aims to determine the adverse effects of tofacitinib and etanercept in the treatment of rheumatoid arthritis in 44-45 year-old adults. Methodology: A systematic literature review was conducted, considering clinical trials and case reports. The search was carried out in PubMed, Scopus, and Web of Science databases, and 11 studies were chosen. The risk of bias was assessed using the Cochrane Systematic Reviews tool. Results: Eleven studies were considered according to the eligibility criteria, and they determined that the most common adverse effects were skin infections, with the highest percentage of 28%. In addition, the risk of developing cancer was notably lower in the group of patients using Tumor Necrosis Factor (TNF) inhibitors compared to those using non-biological disease-modifying antirheumatic drugs as treatment, both before and after administration of the drugs. Discussion: Various studies determined that, among dermatological and subcutaneous alterations, pruritus was mentioned as the most frequent; in infections and infestations, nasopharyngitis was the most frequent, followed by cystitis and pneumonia. Conclusion: The study indicates that TNF inhibitors significantly reduce the risk of patients developing cancer compared to tofacitinib. However, it is associated with a higher rate of pulmonary thrombosis. Common adverse reactions include pruritus, pain at the injection site, and several infections, with some severe complications such as sepsis.